GANTRISIN
LOE ApproachingNDAORALTABLET
Approved
Jul 1948
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 13h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GANTRISIN is an oral tablet small-molecule drug approved in 1948 by Roche. The generic name and mechanism of action are not currently available in this dataset. This is a legacy product nearing loss of exclusivity.
LOE Approaching
This legacy product is approaching loss of exclusivity with moderate competitive pressure (30%), suggesting a declining team structure and focus on generic transition management.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
GANTRISIN offers minimal growth-oriented career opportunities; roles are primarily defensive and operational, focused on managing the transition to generics and maintaining regulatory compliance. This is a suitable opportunity for professionals seeking stable, specialized regulatory or operations expertise rather than brand growth or commercial expansion.
Regulatory Affairs Specialist
Worked on GANTRISIN at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.